The collateral damage of COVID-19 on CVD – discussion.
27 August 2021
ESC Premium Access
COVID-19 and the risk of thrombosis.
27 August 2021
ESC Premium Access
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage